1. Increased Serum Levels of Circulating CD40 Ligand in Patients with Bullous Pemphigoid: Preliminary Results
- Author
-
Norihito Yazawa, Nobuko Ishiura, Yayoi Tada, Rei Watanabe, Manabu Fujimoto, Yoshihiro Kuwano, Kunihiko Tamaki, Hitoshi Okochi, and Hiroko Nakashima
- Subjects
Adult ,Male ,Pathology ,medicine.medical_specialty ,Adolescent ,CD40 Ligand ,Dermatology ,medicine.disease_cause ,Autoimmune Diseases ,Autoimmunity ,Recurrence ,Pemphigoid, Bullous ,medicine ,Humans ,skin and connective tissue diseases ,Aged ,Aged, 80 and over ,Autoimmune disease ,integumentary system ,biology ,Cell adhesion molecule ,business.industry ,Pemphigus vulgaris ,Autoantibody ,Mucous membrane ,Middle Aged ,medicine.disease ,eye diseases ,medicine.anatomical_structure ,Immunology ,biology.protein ,Female ,sense organs ,Bullous pemphigoid ,Antibody ,business ,Pemphigus - Abstract
Background: Autoimmune bullous diseases are characterized by autoantibodies against specific adhesion molecules of the skin and/or mucous membrane. While these autoantibodies are known to play a primary role in the disease manifestation, it remains unknown how disease-specific autoreactive B cells and autoantibodies are induced. Recent studies have indicated the importance of the CD40 and CD40 ligand (CD40L) receptor-ligand pair in the immunopathogenesis of autoimmune diseases. CD40L circulates in soluble form, and some reports suggest that serum soluble CD40L (sCD40L) levels are increased in various autoimmune diseases. Objectives: To determine serum sCD40L levels in patients with pemphigus vulgaris (PV) and bullous pemphigoid (BP), and to determine their correlation with clinical findings and laboratory findings. Patients and Methods: Sera from 10 PV patients, 35 BP patients and 12 normal controls were subjected to ELISA assays to measure serum levels of sCD40L, anti-desmoglein-3 antibody and anti-BP180 antibody. Results and Conclusions: Circulating sCD40L levels were significantly elevated in BP patients, but not in PV patients. Serum sCD40L levels increased in the early stage of disease onset and recurrence in BP patients. In conclusion, circulating sCD40L levels may be a useful marker for early activation of autoimmune diathesis and, furthermore, an effective therapeutic target in patients with BP.
- Published
- 2007